Universal cancer peptides derived from telomerase
US10695409B2 · kind B2 · utility
0Cited by
4References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 31, 2017 |
| Grant date | Jun 30, 2020 |
| Priority date | — |
| Expiry date | May 31, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/9128
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.